{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:42:07Z","timestamp":1759383727084,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40123-021-00381-y","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:09:18Z","timestamp":1628532558000},"page":"935-945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results"],"prefix":"10.1007","volume":"10","author":[{"given":"Martin","family":"Stattin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Graf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kickinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Krepler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-4686","authenticated-orcid":false,"given":"Siamak","family":"Ansari-Shahrezaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"issue":"18","key":"381_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","journal-title":"N Engl J Med"},{"key":"381_CR2","unstructured":"Coronavirus. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. Updated 20 Apr 2021. Accessed 16 May 2020."},{"key":"381_CR3","unstructured":"Coronavirus - Aktuelle Ma\u00dfnahmen. https:\/\/www.sozialministerium.at\/Informationen-zum-Coronavirus\/Neuartiges-Coronavirus-(2019-nCov).html. Updated 20 Apr 2021. Accessed 19 Apr 2020."},{"key":"381_CR4","unstructured":"Gemeinsam gegen das Coronavirus. https:\/\/www.oesterreich.gv.at\/public.html. Updated 5 Feb 2021. Accessed 28 Apr 2020."},{"issue":"5","key":"381_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2019","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2019;127(5):616\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004.","journal-title":"Ophthalmology"},{"issue":"1","key":"381_CR6","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1111\/aos.13840","volume":"97","author":"M Stattin","year":"2019","unstructured":"Stattin M, Forster J, Graf A, Ahmed D, Krebs I, Ansari-Sharezaei S. Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Acta Ophthalmol. 2019;97(1):e131\u20133. https:\/\/doi.org\/10.1111\/aos.13840.","journal-title":"Acta Ophthalmol"},{"key":"381_CR7","doi-asserted-by":"publisher","first-page":"8345850","DOI":"10.1155\/2020\/8345850","volume":"2020","author":"M Stattin","year":"2020","unstructured":"Stattin M, Forster J, Ahmed D, et al. Seven-year visual and anatomical outcomes of intravitreal vascular endothelial growth factor inhibition for neovascular age-related macular degeneration. J Ophthalmol. 2020;2020:8345850. https:\/\/doi.org\/10.1155\/2020\/8345850.","journal-title":"J Ophthalmol"},{"issue":"7","key":"381_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41433-020-0880-6","volume":"34","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Sacconi R, Querques L, et al. Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy. Eye. 2020;34(7):1175\u20136. https:\/\/doi.org\/10.1038\/s41433-020-0880-6.","journal-title":"Eye"},{"issue":"10228","key":"381_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S0140-6736(20)30644-9","volume":"395","author":"The Lancet","year":"2020","unstructured":"The Lancet. COVID-19: protecting health-care workers. Lancet. 2020;395(10228):922. https:\/\/doi.org\/10.1016\/S0140-6736(20)30644-9.","journal-title":"Lancet"},{"issue":"7","key":"381_CR10","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ophtha.2020.03.030","volume":"127","author":"GD Seitzman","year":"2020","unstructured":"Seitzman GD, Doan T. No time for tears. Ophthalmology. 2020;127(7):980\u20131. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.030.","journal-title":"Ophthalmology"},{"issue":"4","key":"381_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/IAE.0000000000002941","volume":"41","author":"F Viola","year":"2021","unstructured":"Viola F, Milella P, Pozzo Giuffrida F, Ganci S, Invernizzi A. Impact of coronavirus disease pandemic on intravitreal injections treatment for macular diseases. Report from a referral hospital in Milan. Retina. 2021;41(4):701\u20135. https:\/\/doi.org\/10.1097\/IAE.0000000000002941.","journal-title":"Retina"},{"key":"381_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-020-01315-x","volume":"25","author":"KYC Teo","year":"2020","unstructured":"Teo KYC, Nguyen V, Barthelmes D, Arnold JJ, Gillies MC, Cheung CMG. Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye. 2020;25:1\u20139. https:\/\/doi.org\/10.1038\/s41433-020-01315-x.","journal-title":"Eye"},{"key":"381_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211010613","author":"MA Sekeroglu","year":"2021","unstructured":"Sekeroglu MA, Kilinc Hekimsoy H, Horozoglu Ceran T, Doguizi S. Treatment of neovascular age related macular degeneration during COVID-19 pandemic: the short term consequences of unintended lapses. Eur J Ophthalmol. 2021. https:\/\/doi.org\/10.1177\/11206721211010613.","journal-title":"Eur J Ophthalmol"},{"key":"381_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.576275","volume":"7","author":"KB Yang","year":"2020","unstructured":"Yang KB, Feng H, Zhang H. Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor treatment in China. Front Med (Lausanne). 2020;7: 576275. https:\/\/doi.org\/10.3389\/fmed.2020.576275 (eCollection 2020).","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"381_CR15","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00417-020-04955-7","volume":"258","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Grosso D, Vella G, et al. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;258(12):2621\u20138. https:\/\/doi.org\/10.1007\/s00417-020-04955-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"381_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jfo.2021.02.001","volume":"44","author":"DY Yeter","year":"2021","unstructured":"Yeter DY, Dursun D, Bozali E, Ozec AV, Erdogan H. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment. J Fr Ophtalmol. 2021;44(3):299\u2013306. https:\/\/doi.org\/10.1016\/j.jfo.2021.02.001.","journal-title":"J Fr Ophtalmol"},{"key":"381_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.38192\/1.6.3.10","volume":"3","author":"M Rahimzadeh","year":"2021","unstructured":"Rahimzadeh M, Muniraju R, Izadi S. Effect of COVID-19 pandemic on anti-VEGF treatment of medical retinal conditions. Physician. 2021;3:1\u201310. https:\/\/doi.org\/10.38192\/1.6.3.10.","journal-title":"Physician"},{"key":"381_CR18","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina. 2017;37:2254\u201361. https:\/\/doi.org\/10.1097\/IAE.0000000000001494.","journal-title":"Retina"},{"issue":"2","key":"381_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","volume":"4","author":"RR Soares","year":"2020","unstructured":"Soares RR, Mellen P, Garrigan H, et al. Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor. Ophthalmol Retina. 2020;4(2):134\u201340. https:\/\/doi.org\/10.1016\/j.oret.2019.07.010.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"381_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","unstructured":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092\u2013101.","journal-title":"Ophthalmology"},{"key":"381_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/OPTH.S90913","volume":"10","author":"AC Pedrosa","year":"2016","unstructured":"Pedrosa AC, Reis-Silva A, Pinheiro-Costa J, et al. Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes. Clin Ophthalmol. 2016;10:541\u20136.","journal-title":"Clin Ophthalmol"},{"issue":"20","key":"381_CR22","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"issue":"4","key":"381_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663\u201371.","journal-title":"Ophthalmology"},{"issue":"7","key":"381_CR24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399\u2013411.","journal-title":"Ophthalmology"},{"issue":"7","key":"381_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/IAE.0b013e3182831265","volume":"33","author":"N Toalster","year":"2013","unstructured":"Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina. 2013;33(7):1351\u20138.","journal-title":"Retina"},{"issue":"3","key":"381_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s12325-017-0484-0","volume":"34","author":"A Danyliv","year":"2017","unstructured":"Danyliv A, Glanville J, McCool R, Ferreira A, Skelly A, Jacob RP. The clinical effectiveness of ranibizumab treat and extend regimen in nAMD: systematic review and network meta-analysis. Adv Ther. 2017;34(3):611\u20139.","journal-title":"Adv Ther"},{"issue":"7","key":"381_CR27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053.","journal-title":"Ophthalmology"},{"issue":"4","key":"381_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","volume":"122","author":"MC Peden","year":"2015","unstructured":"Peden MC, Su\u00f1er IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015;122(4):803\u20138.","journal-title":"Ophthalmology"},{"issue":"8","key":"381_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/aos.13522","volume":"95","author":"K Berg","year":"2017","unstructured":"Berg K, Roald AB, Navaratnam J, Bragad\u00f3ttir R. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol. 2017;95(8):796\u2013802. https:\/\/doi.org\/10.1111\/aos.13522.","journal-title":"Acta Ophthalmol"},{"key":"381_CR30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ophtha.2020.03.030","volume":"258","author":"JF Korobelnik","year":"2020","unstructured":"Korobelnik JF, Loewenstein A, Eldem B, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;258:1149\u201356. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.030.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"381_CR31","unstructured":"COVID-19: Clinical Eye Care. RANZCO. https:\/\/ranzco.edu\/home\/covid-19-information\/clinical-eye-care\/. Updated 9 Mar 2021. Accessed 19 Apr 2020."},{"key":"381_CR32","unstructured":"IVT - Epid\u00e9mie au Covid-19. SFO-online - Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Ophtalmologie. https:\/\/www.sfo-online.fr\/covid-19-infos. Updated 3 Nov 2020. Accessed 7 May 2020."},{"key":"381_CR33","unstructured":"New recommendations for urgent and nonurgent patient care. American Academy of Ophthalmology. https:\/\/www.aao.org\/headline\/new-recommendations-urgent-nonurgent-patient-care. Updated 17 Apr 2020. Accessed 18 Mar 2020."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-021-00381-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T12:53:05Z","timestamp":1636721585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-021-00381-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1007\/s40123-021-00381-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}